FINWIRES · TerminalLIVE
FINWIRES

Dongcheng Pharmaceutical Unit's Market Authorization for Nafamostat Gets China Regulatory Acceptance

By

Yantai Dongcheng Pharmaceutical (SHE:002675) unit Dongcheng North received the acceptance notice issued by China's medical products for the market authorization application for nafamostat mesilate injection.

The drug is indicated for disseminated intravascular coagulation and for preventing blood coagulation during extracorporeal circulation in patients with bleeding tendencies, according to a Monday filing with the Shenzhen bourse.

Shares of the pharmaceutical company closed 1% lower Monday.

Related Articles